1. Introduction {#s0005}
===============

Communicable diseases caused by members of *Enterobacteriaceae* family put a great burden on the society by affecting humans and their livestocks. These infections become quite severe when they are not controlled on time. Some of the examples include pneumonia, pyogenic liver abscess, pyelonephritis and septicemia [@b0005]. The treatment has become difficult due to the emergence of antibiotic resistance among some of the pathogens. Due to the existing challenge of treating these infections with antibiotics, it is inevitable for the research community to look forward to prophylactic means for the prevention of these infections. A large number of vaccine candidates have been proposed by various researchers for specific infections. However, evaluation of individual vaccine candidates under *in-vivo* infection conditions is an enduring task. In the recent years, "Reverse Vaccinology" (RV) has come to play an important role in scrutinizing the vaccine candidates by *in-silico* analysis [@b0010] thereby reducing the time required for ruling out ineffective candidates. This immunoinformatic approach is being frequently used by researchers to predict the epitopes on viruses. This has led to the finding of epitopes on nucleocapsid protein and ovarian tumour domain of Crimean--Congo hemorrhagic fever virus [@b0015]. Another study investigated the variability among epitopes of Hepatitis C virus (HCV) identified in genotype 1 and also predicted the immunogenicity of their variants from other genotypes against South African human leukocyte antigen (HLA) backgrounds [@b0020]. Epitopes of E1 protein isolated from HCV have also been identified using the similar approach [@b0025]. Effective immunogens of MERS-CoV have been discovered through immunoinformatics-driven genome-wide screening strategy [@b0030]. Goodswen et al. [@b0035] have also used this technique for designing protein based vaccines against eukaryotic pathogens. Reverse vaccinology has already been used against other bacterial pathogens like Group B *streptococcus*, where genomic analysis has led to the development of a vaccine composed of four proteins giving protection against all serotypes [@b0040]. Another *In-silico* study has found a protein Bam A of *Acinetobacter baumanii* to be a potential immunogen [@b0045]. RV has also been implied to predict the potential vaccine candidates from the proteome of *Burkholderia pseudomallei* [@b0050]. The outer membrane proteins (OMPs) of these Gram-negative bacteria are usually considered as potent vaccine candidates as they are exposed to the host immune defenses [@b0055]. These OMPs are not always conserved in different genus of bacteria but their lies a probability of presence of some conserved peptide sequence in these OMPs. In this study we have taken into account the proteins which have proved to be potential vaccine candidates on the basis of *in-vivo* research work on animal models. Yersiniabactin receptor FyuA is highly conserved protein prevalent in various members of *Enterobacteriaceae*. As per the reports, FyuA mediates the uptake of ferric-yersiniabactin [@b0060], [@b0065] confirming its role in the virulence of bacteria, which makes it an important vaccine candidate. Moreover researchers have found it as a potential vaccine candidate against pyelonephritis in a murine model of urinary tract infection [@b0070]. It has also been found to be protective in murine model of pneumonia caused by *K. pneumoniae* 43816 in our laboratory (manuscript under communication). The Flagellin protein is another potential vaccine candidate which has been included in this study. Various studies have established the role of flagellin in inducing a systemic inflammatory response via intraperitoneal and intravenous administration [@b0075], [@b0080] and a local inflammatory response with intraintestinal administration [@b0085], [@b0090]. In our lab, flagellin of *Stenotrophomonas maltophilia* has been shown to induce non-specific immune response which protected mice against subsequent bacterial challenge [@b0095]. In the current study both of these vaccine candidates have been analyzed using IEDB server to design a novel *in-silico* vaccine construct harbouring the properties of both these proteins.

2. Methodology {#s0010}
==============

2.1. Protein sequence retrieval {#s0015}
-------------------------------

Gene sequence of FyuA accession no. NC_011751.1 and Flagellin NC_010943.1 were taken from NCBI database [@b0100]. The obtained gene sequences were translated into the protein sequences using Expasy-Translate tool (Swiss Institute of Bioinformatics).

2.2. B-cell linear epitope prediction {#s0020}
-------------------------------------

Protein sequences of Yersiniabactin receptor of *Escherichia coli* UMN026 and Flagellin of *Stenotrophomonas maltophilia* were analyzed for the presence of linear epitopes using Bepipred portal of IEDB server. Both proteins were also analyzed on other algorithms, Parker hydrophilicity prediction, Emini Surface Accessibility Prediction [@b0105]. Antigenicity prediction was done according to Kolaskar and Tongaonkar scale. Prediction of Beta-Turns was done by Chou and Fasman scale on IEDB server.

2.3. Conformational B-cell epitope prediction {#s0025}
---------------------------------------------

Conformational epitopes on yersiniabactin receptor were predicted using Discotope portal of IEDB server by analyzing solvent-accessibility.

2.4. MHC class I and II binding peptide prediction {#s0030}
--------------------------------------------------

In human population Major Histocompatibility complexes (MHC-I and MHC-II) are encoded by human leukocyte antigen (HLA) alleles and are required for the presentation of antigen to T cells. The peptides which could bind to MHC I molecules were predicted by MHC class I binding peptide prediction portal on IEDB server using the consensus method. Interactions were evaluated in terms of percentile ranks. Similarly, peptides binding to MHC II molecules were predicted by MHC class II binding peptide prediction portal on IEDB server using the consensus method.

2.5. Docking {#s0035}
------------

3D structures of alleles were retrieved from RCSB PDB database [@b0110]. Predicted peptide sequences and 3D structure of MHC class I and Class II alleles were submitted to CABS Dock server for docking and simulation studies [@b0115]. Secondary structures of peptides were generated from PSIPRED [@b0120]. The simulation time was set to 50 cycles. The results were clustered according to the distance between the residues of the peptide and MHC molecules.

2.6. Gene sequence analysis of both genes for common site of restriction enzyme {#s0040}
-------------------------------------------------------------------------------

Both gene sequences were analyzed on NEB cutter for mapping restriction sites. The enzymes which could cut the DNA at only single site were identified and the one that was common in both sequences was selected.

2.7. Strategy for construction of chimeric construct by ligation of fragments from FyuA and Flagellin {#s0045}
-----------------------------------------------------------------------------------------------------

The chimeric construct could be constructed after ligation of gene fragments excised from FyuA and Flagellin. Briefly, both the genes could be digested with AatII to produce linear sticky ended fragments of 7.4 and 6.5 kb respectively. AatII will digest FyuA at position 1475 bp and Flagellin at position 188 bp. These fragments could then be digested with *XhoI* to generate sticky ended fragments of 6.9 kb and 0.5 kb from FyuA and 5.5 kb and 0.9 kb from Flagellin. The 0.9 kb fragment from Flagellin and 6.9 kb fragment from FyuA could be ligated with T4 DNA ligase followed by transformation, screening and sequencing.

2.8. ORF analysis of chimeric construct AKSC2 {#s0050}
---------------------------------------------

Open reading frame for the sequence of chimeric gene was analyzed on Expasy-Translate tool (Swiss institute of Bioinformatics).

2.9. Dimensional modeling and stability analysis {#s0055}
------------------------------------------------

The model structure of the chimera AKSC2 was generated using Modeller 9.20 [@b0125]. The structure was energy minimized and validated using Molprobity [@b0130] server for its stereophysical characteristics.

2.10. Linear epitope analysis of AKSC2 {#s0060}
--------------------------------------

Protein sequence of AKSC2 was analyzed using Bepipred portal of IEDB server. The obtained linear epitopes were analyzed for changes in comparison to the epitopes predicted from the individual proteins. The epitopes were also analyzed for the presence of overlapping regions between individual proteins.

2.11. MHC class I and class II binding peptide prediction for AKSC2 {#s0065}
-------------------------------------------------------------------

Protein sequence of AKSC2 was analyzed to observe the peptides which could bind to MHC class I molecules. These peptides were predicted using MHC class I binding peptide prediction portal on IEDB server. Similarly, peptides binding to MHC II molecules were predicted using MHC class II binding peptide prediction portal on IEDB server. Interactions were evaluated in terms of percentile ranks.

3. Results and discussion {#s0070}
=========================

3.1. B-cell linear epitope prediction {#s0075}
-------------------------------------

Amino acid sequences of both the proteins were analyzed for the presence of linear epitopes using the Bepipred prediction tool of IEDB server. For FyuA a threshold score of 0.332 for a window size of 7 amino acids was generated in the portal. Results in [Fig. 1](#f0005){ref-type="fig"} (A) show that a large number of linear epitopes are present in FyuA and most of the prominent epitopes were in the region from amino acid position 20 to 520. The maximum score of 2.317 was obtained for the amino acids near position 160. Similarly, linear epitopes were predicted for Flagellin with the Bepipred generated threshold value of 0.316 for a window size of 7 amino acids. Results in [Fig. 1](#f0005){ref-type="fig"}(B) show a large number of linear epitopes on Flagellin and most of the prominent epitopes were in the region from amino acid position 20 to 380. The maximum value of 1.680 was obtained for the amino acids near position110. The peptides that were significant linear epitopes are shown here in [Table 1](#t0005){ref-type="table"} . Results of Bepipred prediction as shown in [Fig. 1](#f0005){ref-type="fig"} revealed the presence of a wide range of linear epitopes on both FyuA and Flagellin proteins. These results were further verified using other parameters like hydrophilicity, surface accessibility and antigenicity. Similar results were obtained from all the above predictions as both the proteins were found to possess large number of linear epitopes ([Supplementary information](#s0150){ref-type="sec"} SI.1.). The region accommodating the maximum number of epitopes was then selected to be taken further for theoretical construction of chimaera. Further, evaluation of other parameters was done by keeping the selected regions into consideration. Since, there lies a possibility that the chimeric protein may not take up the proper folding when over expressed due to physical constraint of large size. Hence, it may be expressed as inclusion bodies when subjected to over expression. Misfolding of protein would certainly not affect the T- cell dependent response since the generation of T-cell response depends on the processing and presentation of peptides on MHC molecules but it may affect the antibody response to conformational epitopes. However, Results in [Table 1](#t0005){ref-type="table"}show some large linear epitopes of length upto 34, 23, 22 and 26 amino acids in the peak number 2, 8, 10 and 14 respectively in FyuA protein. Whereas, most of the epitopes in Flagellin were not large and the maximum length of a large epitope was 20 amino acids as shown by peak number 20 in [Table 1](#t0005){ref-type="table"}. Therefore, the presence of linear epitopes can be considered as a very significant feature of the vaccine candidate protein as it could help in the generation of antibody response even if the protein is administered in denatured form.Fig 1Linear epitope prediction from the protein sequences FyuA (A) and Flagellin (B) using Bepipred prediction portal of IEDB server. The yellow peaks show the peptide sequences that are potential epitopes whereas the green peaks show the peptides that are not epitopic in nature. The encircled area on the graphs shows the region of protein having higher frequency of epitopic peptides.Table 1. Significant linear peptides predicted from FyuA and Flagellin protein sequence.Peptides predicted from FyuA protein sequencePeak. NoStartEndPeptideLength12130NAQTSQQDES1023770SKQSSRSASANNVSSTVVSAPELSDAGVTASDKL347137147QGTLYGKSAQG118154176TQQPDSTPRGYIEGGVSSRDSYR2310201222DDGDMINPATGSDDLGGTRASI2211229238LAPDDQPWEM1012245255ECTRATQDAYV1114266291SISDGSPDPYMRRCTDSQTLSGKYTT2615304312QQHYSRTFP919352364NTREKLNSAYDMP1320366379MPYLSSTGYTTAET1423401411RFSHDKSSTQY1124417431GNPFGDQGKSNDDQV1525452463AQGYKPSGYNIV1231512530PVGMQTLSNAGKADATGVE1938571581RYGAGSSVNGV1139602612YFDGDNQLRQG11  Peptides predicted from Flagellin protein sequencePeak. NoStartEndPeptideLength11725NLSTSGSSL923547GSRINSAKDDAAG1346571IRNANDG7798112QASNATNSASDRKAL158126133VAKQSDFN812163170IDAKANAL814180194IAAPTLTGTPATTAD1516214225VENTDAAGAGKA1218240246LAEADAT720270289TGGVTVAGNTTVPARQYADK2024334342QTSSENLSA925345355SRIKDTDFAKE11

3.2. Conformational B-cell epitope prediction {#s0080}
---------------------------------------------

Conformational epitopes of FyuA were predicted using Discotope tool on IEDB server. Results in [Fig. 2](#f0010){ref-type="fig"} (A) as depicted by the green peaks is the region from amino acid position 200 to 400 that possess maximum conformational epitopes. These epitopes (yellow) were also shown on the 3-D structural image created by J-mol-PDB [Fig. 2](#f0010){ref-type="fig"}(B). Since most of the conformational epitopes are present on the exposed surface, these epitopes may become a target of antibodies for effectively neutralizing the bacteria during infection. Both the protein could prove to be good vaccine candidates if they are able to generate both B cell as well T cell responses. However, both the proteins qualified for the generation of B cell response therefore predictions were made for their ability to generate T-cell responses. This was done by predicting MHC class I and II binding peptides.Fig 2Presence of discontinuous or conformational epitopes for FyuA protein using Discotope tool on IEDB server. (A) The result window shows the presence of discontinuous epitopes in the form of green peaks. (B) The 3D structure shows the presence of conformational epitopes in yellow colour on various parts of protein. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

3.3. MHC class I binding peptide prediction {#s0085}
-------------------------------------------

MHC Class I binding peptides were predicted using the MHC Class I binding prediction tool on IEDB server. Peptides with a percentile rank below 10 were considered significant. Results in [Fig. 3](#f0015){ref-type="fig"} (A) show that 2858 significant interactions were obtained for FyuA protein and among these, 2017 interactions were from the selected region of amino acid position 1 to 490. Similarly, for Flagellin protein results in [Fig. 3](#f0015){ref-type="fig"}(A) show about 1443 significant interactions and among these, 1226 interactions were from the selected region of amino acid position 61 to 389 ([Supplementary information](#s0150){ref-type="sec"} SI.2.). Therefore the results in [Fig. 3](#f0015){ref-type="fig"}(B) show that 70% of the significant interactions were from the selected region of FyuA and 85% of significant interactions were from the selected region of Flagellin [Fig. 3](#f0015){ref-type="fig"}(B). The top 10 peptides from the selected region having lowest percentile rank were shortlisted and are shown in [Table 2](#t0010){ref-type="table"} . Data in [Table 2](#t0010){ref-type="table"} show that both of these proteins possessed significant number of peptidic regions that could bind to MHC class I molecules and presented to CD8^+^ T-cells. Population having the alleles shown in [table 2](#t0010){ref-type="table"} were determined using the [allelefrequencies.net](http://allelefrequencies.net){#ir005} and the allele HLA-A\*30:02 and HLA-A\*53:01 are found in South African population, HLA-A\*35:01 is present in USA, Mexico and Oman. HLA-A\*26:01 and HLA-A\*68:01 are found among Asians and Europeans. HLA-A\*01:01 is found in Ireland, USA and Uganda. It is also seen that the peptides of both these proteins bind with different alleles which are present in different parts of world. This difference in the binding will turn out to be very beneficial when AKSC2 will be used as vaccine as more the number of binding alleles more would be the coverage of human population.Fig 3Comparative number (A) and percentage (B) of peptide interactions from the selected (SR) and non-selected regions (NSR) of FyuA and Flagellin respectively.Table 2. Predicted MHC I binding peptides from the selected region of FyuA and Flagellin.Peptides from FyuAAllelestartendlengthpeptideMethodPercentile rankHLA-A\*30:0234034910RTVDMVFGLYConsensus (ann/smm)0.06HLA-B\*35:013663749MPYLSSTGYConsensus (ann/comblib_sidney2008/smm)0.1HLA-A\*26:013753839TTAETLAAYConsensus (ann/smm)0.11HLA-A\*68:0185939MLFSTISLRConsensus (ann/smm)0.11HLA-A\*01:012672759ISDGSPDPYConsensus (ann/smm)0.12HLA-A\*01:013413499TVDMVFGLYConsensus (ann/smm)0.12HLA-A\*30:0244645510RVYTRVAQGYConsensus (ann/smm)0.13HLA-A\*68:0134135010TVDMVFGLYRConsensus (ann/smm)0.14HLA-B\*53:0131132010FPSGSLIVNMConsensus (ann/smm)0.14HLA-B\*51:01707910LPRVLPGLNIConsensus (ann/smm)0.14  Peptides from FlagellinAllelestartendlengthPeptideMethodPercentile rankHLA-A\*02:061121209LQAEVTQLVConsensus (ann/smm)0.11HLA-A\*68:0237338210ETAELTRTQIConsensus (ann/smm)0.14HLA-A\*68:01445310DAAGLAISERConsensus (ann/smm)0.17HLA-A\*68:022332419MVAAINAKIConsensus (ann/comblib_sidney2008/smm)0.2HLA-B\*44:0311412310AEVTQLVSEIConsensus (ann/smm)0.23HLA-A\*68:0223324210MVAAINAKIGConsensus (ann/smm)0.24HLA-A\*02:0117318210AMFDSVSFTIConsensus (ann/smm)0.25HLA-A\*30:0191999RVRELSVQAConsensus (ann/comblib_sidney2008/smm)0.3HLA-A\*02:0317318210AMFDSVSFTIConsensus (ann/smm)0.3HLA-B\*44:023753839AELTRTQILConsensus (ann/smm)0.3

3.4. MHC class II binding peptide prediction {#s0090}
--------------------------------------------

Peptides binding to MHC class II molecules were predicted using MHC class II binding peptide prediction tool on IEDB server. For MHC class II binding, IEDB recommended method and a reference set of 27 alleles was used. Results in [Fig. 3](#f0015){ref-type="fig"}(A) show that 2018 significant interactions were obtained for FyuA protein. Out of which 1479 interactions with the reference set of alleles were from the selected region. Similarly, for Flagellin protein results in [Fig. 3](#f0015){ref-type="fig"}(A) show that 1353 significant peptide allele interactions were predicted by the server and among these, 1168 interactions were from the selected region ([Supplementary information](#s0150){ref-type="sec"} SI.2.). Also the results in [Fig. 3](#f0015){ref-type="fig"}(B) show that 73% of the significant interactions were from the selected region of FyuA and 86% of significant interactions were from the selected region of Flgellin [Fig. 3](#f0015){ref-type="fig"}(B). [Table 3](#t0015){ref-type="table"} depict the top 10 peptides from the selected region having lowest percentile rank for FyuA for Flagellin respectively. Alleles HLA-DRB3\*01:01, HLA-DRB1\*09:01 and HLA-DRB1\*08:02 are present largely in Asian and Russian populations ([allelefrequencies.net](http://allelefrequencies.net){#ir010}). Allele HLA-DQA1\*01:02/DQB1\*06:02 is found in Asian, African, Israel and French populations and HLA-DQA1\*04:01/DQB1\*04:02 is present in German, African and Asian populations.Table 3. Predicted MHC II binding peptides from the selected region of FyuA and Flagellin.Peptides from FyuAAlleleStartEndPeptideMethod usedPercentile rankHLA-DRB3\*01:01435449LSAGYMLTDDWRVYTConsensus (comb.lib./smm/nn)0.01HLA-DRB3\*01:01436450SAGYMLTDDWRVYTRConsensus (comb.lib./smm/nn)0.01HLA-DRB3\*01:01437451AGYMLTDDWRVYTRVConsensus (comb.lib./smm/nn)0.01HLA-DRB3\*01:01438452GYMLTDDWRVYTRVAConsensus (comb.lib./smm/nn)0.01HLA-DRB3\*01:01434448QLSAGYMLTDDWRVYConsensus (comb.lib./smm/nn)0.02HLA-DRB3\*01:01439453YMLTDDWRVYTRVAQConsensus (comb.lib./smm/nn)0.03HLA-DRB1\*09:01115MKMTRLYPLALGGLLConsensus (comb.lib./smm/nn)0.08HLA-DRB1\*08:021327GLLLPAIANAQTSQQConsensus (smm/nn/sturniolo)0.08HLA-DRB1\*08:021428LLLPAIANAQTSQQDConsensus (smm/nn/sturniolo)0.1HLA-DRB3\*01:01433447GQLSAGYMLTDDWRVConsensus (comb.lib./smm/nn)0.15  Peptides from FlagelinAlleleStartEndPeptideMethod usedPercentile rankHLA-DQA1\*01:02/DQB1\*06:02380394TQILQQAGTAMLAQAConsensus (comb.lib./smm/nn)0.01HLA-DQA1\*01:02/DQB1\*06:02381395QILQQAGTAMLAQANConsensus (comb.lib./smm/nn)0.01HLA-DQA1\*01:02/DQB1\*06:02382396ILQQAGTAMLAQANQConsensus (comb.lib./smm/nn)0.01HLA-DQA1\*01:02/DQB1\*06:02383397LQQAGTAMLAQANQVConsensus (comb.lib./smm/nn)0.01HLA-DQA1\*01:02/DQB1\*06:02384398QQAGTAMLAQANQVPConsensus (comb.lib./smm/nn)0.01HLA-DQA1\*01:02/DQB1\*06:02379393RTQILQQAGTAMLAQConsensus (comb.lib./smm/nn)0.03HLA-DQA1\*04:01/DQB1\*04:02239253AKIGETGVLAEVDAAConsensus (comb.lib./smm/nn)0.1HLA-DRB4\*01:01377391LTRTQILQQAGTAMLConsensus (comb.lib./smm/nn)0.19HLA-DRB1\*09:01175189FDSVSFTIAAPADATConsensus (comb.lib./smm/nn)0.21HLA-DRB1\*09:01176190DSVSFTIAAPADATTConsensus (comb.lib./smm/nn)0.21

3.5. Docking and simulations {#s0095}
----------------------------

Results obtained after simulated 3-Dimensional docking of predicted peptides with the predicted MHC molecules were presented in [Table 5](#t0025){ref-type="table"}, [Table 6](#t0030){ref-type="table"}. The data shows the average RMSD values of the each peptide-MHC complex. The average RMSD values between 3 and 5 are considered of medium accuracy whereas the values below 3 are considered as highly accurate [@b0135]. Along with the RMSD values the distance between the interacting amino acid residues of MHC molecules and that of the interacting peptide was also analyzed. The results in [Table 5](#t0025){ref-type="table"}and [Fig. 4](#f0020){ref-type="fig"} show that the MHC class I and class II binding peptide predictions made using the IEDB server, were also found to be significantly accurate using the 3-D simulations for docking. This could be interpreted as the values of average RMSD were below 5 in the simulated complexes. The interacting residues shown in the table were lying at a distance of \<3 Å.Fig 4Peptide-MHC complexes obtained after 3D simulations using CABS server.

3.6. Proposed strategy for construction of chimaeric construct by ligation of fragments from FyuA and Flagellin {#s0100}
---------------------------------------------------------------------------------------------------------------

These results of all the *in-silico* predictions helped us in choosing the regions from both the proteins, so that they could be combined to produce a single chimaeric construct. We therefore propose a strategy which could lead to the formation of the chimaeric construct. For designing the chimaeric gene construct, cloning strategy was adopted using genetic engineering tool for restriction digestion. Gene sequences of both the proteins were analyzed on NEB cutter tool of New England Biolabs. Restriction enzyme AatII ([Supplementary information](#s0150){ref-type="sec"} SI.1.) was found to be present in both the protein sequences and cleaves FyuA at position 1475 and Flagellin at position 188 and generates sticky ends. [Fig. 5](#f0025){ref-type="fig"} shows the graphical representation of the cloning strategy.Fig 5Graphical representation of the process for the construction of chimaera AKSC2.

3.7. ORF analysis of chimeric construct {#s0105}
---------------------------------------

*In-silico* created chimeric construct was found to be consisting of 2454 base pairs ([Supplementary information](#s0150){ref-type="sec"} SI.1.) which was further translated using Expasy/Translate tool and a protein of 817 amino acids was formed to give a molecular weight of approximately 90 KDa ([Supplementary information](#s0150){ref-type="sec"} SI.1.). This ruled out the presence of any stop codon within the whole sequence. The main objective of combining large gene fragments from both the proteins was considered so as to provide the cellular protein processing machinery with enough of proteasome cleavage sites. The possibility of a single peptide to act as a vaccine is usually a rare chance. Hence a protein can be processed to in different ways to create epitopes whose presentation to T-cells may add to protection during pathogenesis.

3.8. Dimensional modeling and stability analysis {#s0110}
------------------------------------------------

Analysis of Ramachandran plot of the chimera AKSC2 generated using the Molprobity server suggested that 94.2% residues lied in the favoured and allowed region while only 5.8% residues were in the outlier region ([supplementary information](#s0150){ref-type="sec"} SI.3.). The obtained values suggest that the model is structurally stable.

3.9. Linear epitope analysis of AKSC2 {#s0115}
-------------------------------------

Further analysis of AKSC2 showed an increase in the average threshold value in linear epitope prediction this probably resulted by combining the two proteins ([Fig. 6](#f0030){ref-type="fig"} ). There were also the peptides in AKSC2 that were epitopic and lied in the region joining both the proteins. This was another advantage of this chimaera as these overlapping peptides could increase the population coverage of vaccine.Fig 6Comparative threshold of peptide prediction in comparison to all three vaccine candidates.

3.10. Overlapping epitopes in AKSC2 {#s0120}
-----------------------------------

[Table 4](#t0020){ref-type="table"} show the peptides that are able to bind to MHC class I and Class II and are present in the region joining the two proteins. These peptides are able to bind to different alleles.Table 4. Overlapping peptides binding with MHC class I and class II molecules.MHC Class IAlleleStartEndPeptideMethod usedPercentile rankHLA-A\*68:02487496ETADVAIRNAConsensus (ann/smm)0.47HLA-A\*68:02487495ETADVAIRNConsensus (ann/comblib_sidney2008/smm)0.92HLA-A\*24:02485493RYETADVAIConsensus (ann/smm)1.1HLA-A\*26:01487496ETADVAIRNAConsensus (ann/smm)1.55HLA-A\*23:01485493RYETADVAIConsensus (ann/smm)1.7HLA-A\*30:01483491GTRYETADVConsensus (ann/comblib_sidney2008/smm)2.4HLA-B\*40:01486494YETADVAIRConsensus (ann/smm)2.4HLA-A\*68:01486494YETADVAIRConsensus (ann/smm)3.05HLA-A\*68:01487495ETADVAIRNConsensus (ann/smm)3.4HLA-A\*24:02485494RYETADVAIRConsensus (ann/smm)3.5HLA-A\*31:01485494RYETADVAIRConsensus (ann/smm)3.55HLA-B\*40:01486495YETADVAIRNConsensus (ann/smm)4.25HLA-A\*32:01485493RYETADVAIConsensus (ann/comblib_sidney2008/smm)4.3HLA-A\*26:01487495ETADVAIRNConsensus (ann/smm)4.95HLA-B\*44:03486494YETADVAIRConsensus (ann/smm)5.2HLA-B\*58:01488497TADVAIRNANConsensus (ann/smm)5.3HLA-A\*33:01485494RYETADVAIRConsensus (ann/smm)5.45HLA-A\*01:01487496ETADVAIRNAConsensus (ann/smm)5.95HLA-B\*44:02486494YETADVAIRConsensus (ann/smm)6.35HLA-A\*33:01486494YETADVAIRConsensus (ann/smm)6.9HLA-B\*51:01484493TRYETADVAIConsensus (ann/smm)7.5HLA-B\*40:01485493RYETADVAIConsensus (ann/smm)7.6HLA-A\*23:01485494RYETADVAIRConsensus (ann/smm)7.9HLA-A\*02:03483491GTRYETADVConsensus (ann/smm)8.8HLA-A\*30:01485493RYETADVAIConsensus (ann/comblib_sidney2008/smm)9.9  **MHC Class II**AlleleStartEndPeptideMethod usedPercentile rankHLA-DRB1\*08:02480494YELGTRYETADVAIRConsensus (smm/nn/sturniolo)6.69HLA-DRB5\*01:01480494YELGTRYETADVAIRConsensus (smm/nn/sturniolo)7.03HLA-DRB5\*01:01481495ELGTRYETADVAIRNConsensus (smm/nn/sturniolo)7.03HLA-DRB5\*01:01482496LGTRYETADVAIRNAConsensus (smm/nn/sturniolo)7.03HLA-DRB5\*01:01483497GTRYETADVAIRNANConsensus (smm/nn/sturniolo)7.03HLA-DRB5\*01:01484498TRYETADVAIRNANDConsensus (smm/nn/sturniolo)7.03HLA-DRB3\*01:01479493NYELGTRYETADVAIConsensus (comb.lib./smm/nn)7.99HLA-DRB3\*01:01480494YELGTRYETADVAIRConsensus (comb.lib./smm/nn)7.99HLA-DRB3\*01:01481495ELGTRYETADVAIRNConsensus (comb.lib./smm/nn)7.99HLA-DRB3\*01:01482496LGTRYETADVAIRNAConsensus (comb.lib./smm/nn)7.99HLA-DRB3\*01:01483497GTRYETADVAIRNANConsensus (comb.lib./smm/nn)7.99HLA-DRB3\*01:01484498TRYETADVAIRNANDConsensus (comb.lib./smm/nn)7.99HLA-DRB3\*01:01485499RYETADVAIRNANDGConsensus (comb.lib./smm/nn)7.99Table 5. Structural clustering between MHC molecules and predicted peptides from FyuA and Flagellin.AllelePeptideRMSDInteracting residuesDistance (A^o^)FyuAReceptorPeptideHLA-A\*68:01MLFSTISLR4.156THR A 233PHE 32.537THR A 233SER 42.697TYR B 63SER 42.731TYR B 63THR 52.733TYR B 26SER 42.769HLA-B\*35:01MPYLSSTGY3.970TYR A 7THR 72.670THR A 143MET 12.715ASN A 63TYR 92.737TYR A 159GLY 82.779TYR A 59TYR 92.786HLA-DRB1\*08:02LLLPAIANAQTSQQD2.371ASN A 62ALA 72.73TYR B 78GLN132.735VAL B 11PRO 42.74ASN B 82GLN 142.742ASN A 69LEU 32.745HLA-DRB3\*01:01LSAGYMLTDDWRVYT4.023THR 83THR 152.631THR A 80TYR 142.705TYR A 13TRP 112.729ASP A 66TRP 112.754ILE A 82THR 152.808FlagellinHLA-A\*02:01AMFDSVSFTI1.418SER A 4ILE 102.675ARG A6PHE 82.758SER B 57ASP 42.853ASP A 30SER 72.863PRO A 235SER 52.868HLA-A\*02:06LQAEVTQLV0.421ASP A 30THR 62.653GLN A 32VAL 92.738TYR A 113LEU 12.744LEU A 126LEU 12.763GLU A 212GLU 42.796HLA-DRB4\*01:01LTRTQILQQAGTAML2.236ASN A 69LEU 12.532ASN A 69ARG 32.653LEU B 67GLN 52.667PHE A 54MET 142.722VAL B 85LEU 152.735Table 6. Structural clustering between the predicted alleles and peptides of overlapping region adjoining the two proteins.AllelePeptideRMSDInteracting residuesDistance (A^o^)ReceptorPeptideHLA-A\*68:02ETADVAIRNA0.574PHE A 33VAL 52.732TYR A 99GLU 12.737PHE A 33ALA 62.761ASN A 63ASP 42.785ASN A 174ASN 92.816HLA-A\*68:02ETADVAIRN1.287TYR A 7ARG 82.703THR A 73ASP 42.806ASP A 77GLU 12.832HIS A 114ALA 32.834GLN A 70ALA 62.847HLA-A\*68:02YETADVAIR0.643VAL A 34ARG 92.734VAL A 152GLU 22.739ASN A 66VAL 62.742ARG A 97TYR 12.768THR A 73THR 32.771HLA-B\*58:01TADVAIRNAN1.931THR A 73ASN 82.575TYR 9ASP 32.65THR A 143ASN 102.669SER A 116ARG 72.726ARG A 97ALA 52.732HLA-DRB3\*01:01NYELGTRYETADVAI3.0601THR A 113TYR 22.673GLN A 9GLU 92.707PHE A 24VAL 132.735ILE A 7VAL 132.738GLU A 11THR 62.740HLA-DRB3\*01:01YELGTRYETADVAIR1.747ASN A 62THR 52.704ASP B 57LEU 32.744TYR B 78ARG 62.867THR B 77ARG 63.008GLY A 58TYR 73.011HLA-DRB5\*01:01ELGTRYETADVAIRN4.839VAL A 91ALA 122.565GLU B 4LEU 22.740LYS B12GLU 12.744VAL A 91VAL 112.745ASP A 27TYR 62.766

Results in [Table 7](#t0035){ref-type="table"} show the similarity of overlapping peptides which were generated as a result of fusion of the two proteins. The peptide analyzed using BLASTp showed its identity with peptides present in microorganisms other than the source of peptide. This also gave a hope that the chimaeric vaccine candidate may confer protection upon global populations from the infectious diseases caused by a wide range of pathogens.Table 7. BLAST analysis of overlapping peptides.DescriptionPeptideMax scoreTotal scoreQuery coverE valueIdentAccessionhypothetical protein \[Microbacterium humi\]**ETADVAIRNA**29.529.5100%3591%WP_091187671.1ribosome recycling factor \[Mycoplasma agalactiae\]**ETADVAIRNA**28.628.6100%7090%WP_004024227.1DUF4192 family protein \[Mycobacterium avium\]**ETADVAIRNA**27.827.890%13989%WP_084051761.1hypothetical protein \[Burkholderia sp. AU31652\]**ETADVAIRNA**27.427.480%198100%WP_089433309.1hypothetical protein \[Acinetobacter sp. WCHA45\]**ETADVAIRNA**26.926.990%27789%WP_111313911.1

4. Conclusion {#s0125}
=============

From the *in-silico* analysis it is concluded that reverse vaccinology can be used to create novel chimeric constructs from the already known vaccine candidates to make them more effective and to confer protection among diverse populations against a wide range of enterobacterial pathogens.
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